Study on the Diagnosis of Ground-glass Lung Cancer by Microwave Ablation Combined With Puncture Biopsy
Recruiting · NCT06776588 · Interventional (participants receive a specific treatment)
View the official record on ClinicalTrials.gov →Interventions studied
Microwave ablation combined with biopsy
What this trial is about
This study is a multicenter study. It plans to screen 200 patients with pulmonary nodule lesions with ground glass as the main body, take CT thin-layer scanning 3D reconstruction, apply AI and fragment omics technology to evaluate the risk of malignant transformation of pulmonary nodules, and use microwave ablation to treat pulmonary nodules and combine intraoperative rapid pathology technology to determine the nature of puncture tissue and the degree of ablation, and then explore the optimal ablation time and ablation power.
Who can take part
Age range
18 Years to 75 Years
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not applicable (e.g. observational or device study)
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- Age ≤ 75 years;
- GGN patients with the maximum axial diameter of the lesion in the lung window ≤ 3 cm;
- Refusing radical surgery or being unable to tolerate surgical treatment;
- Normal coagulation function, platelet count ≥ 60 × 109 /L;
- ECOG score ≤ 2 points;
Exclusion criteria
- Patients with the maximum axial diameter of the lesion in the lung window greater than 3 cm
- Platelets \<50×109 /L
- Patients with severe bleeding tendency and coagulation dysfunction that cannot be corrected in the short term
- Severe chronic obstructive pulmonary disease, emphysema, pulmonary fibrosis and pulmonary hypertension
- Patients whose anticoagulant therapy or antiplatelet drugs have been discontinued for less than 5 days before ablation
- Patients with severe heart, liver, kidney and brain dysfunction
- Patients with severe anemia, dehydration and cachexia that cannot be corrected or improved in the short term
- Patients with an estimated survival period of less than 6 months
Where it is running
1 location listed.
- Beidahuang Industry Group General Hospital - Harbin, Heilongjiang, China